Cocrystal Pharma, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of approximately $2.3 million, a slight improvement from a net loss of $2.3 million in the same period of 2025. The company recognized grant income of $225,000 during the quarter, marking its first revenue since the previous year. Total operating expenses increased to $2.6 million from $2.3 million year-over-year, driven primarily by higher general and administrative costs, which rose to $1.2 million from $981,000.
The company's total assets decreased to $7.4 million as of March 31, 2026, down from $9.7 million at the end of 2025. This decline was largely attributed to a reduction in cash and cash equivalents, which fell to $4.7 million from $7.0 million. Cocrystal's stockholders' equity also decreased significantly, from $6.3 million to $4.1 million, reflecting the ongoing operational losses and the accumulation of an accumulated deficit of $344.5 million.
In terms of operational developments, Cocrystal continues to focus on its research and development efforts, particularly in the antiviral drug sector. The company has been actively pursuing government grants to support its initiatives, including a recent $500,000 award from the National Institutes of Health for the development of a novel oral antiviral candidate. The company’s employee headcount remained stable, with 13.8 million shares of common stock outstanding as of March 31, 2026, compared to 13.8 million shares at the end of 2025.
Looking ahead, Cocrystal has expressed concerns regarding its liquidity and ability to continue as a going concern, given its reliance on external funding to support ongoing operations. The company reported that its current resources may not be sufficient to fund operations beyond the next 12 months, emphasizing the need for additional capital to sustain its research and development programs. Cocrystal's management remains focused on securing financing and developing strategic partnerships to enhance its market position and advance its product candidates through clinical trials.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral therapeutics targeting RNA viruses such as influenza, coronaviruses, norovirus, and hepatitis C. Utilizing proprietary structure-based drug design, it aims to create safe, effective, broad-spectrum, and resistance-high barrier antiviral drugs. Its core activities include preclinical and clinical research, with a focus on unmet medical needs in infectious diseases. The company relies on collaborations, third-party manufacturing, and advanced scientific platforms to develop innovative antiviral treatments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.